Insider trading

Period: 120 months Stock: FATE Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

70 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

70 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

70 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

70 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
70 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
70 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

70 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
4 Aug 2026
TAHL CINDY See Remarks
Sold at will
$95.41K 38,800 at 2.46
6.2%
Not planned
20 May 2026
TAHL CINDY See Remarks
Sold at will
$48.08K 25,590 at 1.88
3.9%
Not planned
9 Jan 2026
TAHL CINDY See Remarks
Sold at will
$11.28K 10,589 at 1.06
2.7%
Not planned
4 Aug 2025
TAHL CINDY See Remarks
Sold at will
$9.57K 9,037 at 1.06
2.2%
Not planned
10 Jan 2025
Bressi Jerome Charles See Remarks
Sold at will
$9.27K 5,980 at 1.55
2.2%
Not planned
10 Jan 2025
TAHL CINDY See Remarks
Sold at will
$8.76K 5,654 at 1.55
1.7%
Not planned
9 Jan 2024
Valamehr Bahram Chief R&D Officer
Sold at will
$49.37K 11,271 at 4.38
6.7%
Not planned
9 Jan 2024
TAHL CINDY General Counsel and Secretary
Sold at will
$47.52K 10,874 at 4.37
7.1%
Not planned
9 Nov 2023
TAHL CINDY General Counsel and Secretary
Sold on a plan
$58.47K 24,363 at 2.40
13.7%
Planned (10b5-1)
5 Jul 2023
Powl Brian T. Chief Commercial Officer
Sold at will
$18.77K 3,854 at 4.87
8.6%
Not planned
18 Apr 2023
Chu Yu-Waye Chief Medical Officer
Sold on a plan 2×
$16.65K 2,532 at 6.57
1.8%
Planned (10b5-1)
10 Jan 2023
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$60.54K 11,553 at 5.24
6.1%
10 Jan 2023
Valamehr Bahram Chief R&D Officer
Sold, plan not stated
$57.21K 10,917 at 5.24
6.1%
10 Jan 2023
Chu Yu-Waye Chief Medical Officer
Sold, plan not stated
$41.00K 7,825 at 5.24
5.2%
10 Jan 2023
Plavsic Mark Chief Technical Officer
Sold, plan not stated
$17.91K 3,418 at 5.24
2.7%
7 Jul 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated
$518.69K 17,158 at 30.23
8.7%
6 Jul 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated
$235.81K 7,842 at 30.07
4.2%
5 Jul 2022
Plavsic Mark Chief Technical Officer
Sold, plan not stated
$91.52K 3,719 at 24.61
2.8%
1 Jun 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$574.00K 25,000 at 22.96
11.7%
19 Apr 2022
Chu Yu-Waye Chief Medical Officer
Sold, plan not stated
$143.67K 4,062 at 35.37
2.6%
1 Apr 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$971.25K 25,000 at 38.85
11.7%
14 Mar 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 5×
$776.73K 25,000 at 31.07
12.2%
11 Jan 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 2×
$262.97K 5,419 at 48.53
3.4%
11 Jan 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 2×
$221.66K 4,570 at 48.50
3.0%
11 Jan 2022
Chu Yu-Waye Senior VP Clinical Development
Sold, plan not stated 2×
$192.34K 3,965 at 48.51
3.2%
10 Jan 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 2×
$359.31K 7,738 at 46.43
4.6%
10 Jan 2022
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 2×
$259.56K 5,596 at 46.38
3.6%
3 Jan 2022
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 4×
$2.97M 50,000 at 59.34
22.8%
13 Dec 2021
Valamehr Bahram Chief R&D Officer
Sold, plan not stated 5×
$1.19M 25,000 at 47.66
13.8%
10 Dec 2021
Chu Yu-Waye Senior VP Clinical Development
Sold, plan not stated 7×
$385.95K 7,500 at 51.46
5.6%
1 Oct 2021
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 3×
$2.94M 50,000 at 58.83
31.6%
13 Sep 2021
Valamehr Bahram Chief Development Officer
Sold, plan not stated 3×
$1.66M 25,000 at 66.29
20.7%
1 Jul 2021
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 11×
$4.73M 55,534 at 85.24
33.9%
14 Jun 2021
Valamehr Bahram Chief Development Officer
Sold, plan not stated 3×
$2.23M 25,000 at 89.32
20.7%
16 Apr 2021
Chu Yu-Waye Senior VP Clinical Development
Sold, plan not stated 3×
$272.81K 3,275 at 83.30
4.8%
1 Apr 2021
TAHL CINDY See Remarks
Sold, plan not stated 8×
$2.51M 30,000 at 83.81
21.7%
15 Mar 2021
Valamehr Bahram Chief Development Officer
Sold, plan not stated 5×
$2.31M 25,000 at 92.35
20.7%
8 Mar 2021
Shoemaker Daniel D Chief Scientific Officer
Sold, plan not stated 8×
$2.04M 25,000 at 81.74
25.5%
19 Jan 2021
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 4×
$4.02M 35,000 at 114.76
28.0%
11 Jan 2021
Valamehr Bahram Chief Development Officer
Sold, plan not stated 3×
$360.59K 3,254 at 110.81
4.0%
11 Jan 2021
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 3×
$360.59K 3,254 at 110.81
3.5%
11 Jan 2021
Shoemaker Daniel D Chief Scientific Officer
Sold, plan not stated 3×
$360.48K 3,253 at 110.81
3.7%
8 Jan 2021
Valamehr Bahram Chief Development Officer
Sold, plan not stated 4×
$729.55K 6,230 at 117.10
7.1%
8 Jan 2021
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 4×
$729.43K 6,229 at 117.10
6.3%
8 Jan 2021
Shoemaker Daniel D Chief Scientific Officer
Sold, plan not stated 4×
$729.43K 6,229 at 117.10
6.7%
14 Dec 2020
Valamehr Bahram Chief Development Officer
Sold, plan not stated 8×
$2.44M 25,000 at 97.78
22.3%
16 Nov 2020
Shoemaker Daniel D Chief Scientific Officer
Sold, plan not stated 3×
$1.30M 25,000 at 51.83
21.2%
5 Nov 2020
TAHL CINDY General Counsel and Secretary
Sold, plan not stated 2×
$976.25K 19,282 at 50.63
16.2%
4 Nov 2020
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$2.60M 51,519 at 50.41
34.1%
16 Oct 2020
TAHL CINDY General Counsel and Secretary
Sold, plan not stated
$1.47M 29,199 at 50.25
22.7%
Showing 1–50 of 70. Page 1 of 2 Older →